These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18534018)

  • 1. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
    Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
    Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
    Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
    Yerlikaya A; DoKudur H
    Mol Biol (Mosk); 2010; 44(5):859-66. PubMed ID: 21090173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
    Ishitsuka K; Hideshima T; Neri P; Vallet S; Shiraishi N; Okawa Y; Shen Z; Raje N; Kiziltepe T; Ocio EM; Chauhan D; Tassone P; Munshi N; Campbell RM; Dios AD; Shih C; Starling JJ; Tamura K; Anderson KC
    Br J Haematol; 2008 May; 141(5):598-606. PubMed ID: 18397345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
    Oncogene; 2004 Nov; 23(54):8766-76. PubMed ID: 15480425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
    Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
    Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
    Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
    Khan T; Stauffer JK; Williams R; Hixon JA; Salcedo R; Lincoln E; Back TC; Powell D; Lockett S; Arnold AC; Sayers TJ; Wigginton JM
    J Immunol; 2006 May; 176(10):6302-12. PubMed ID: 16670342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.
    Kern J; Untergasser G; Zenzmaier C; Sarg B; Gastl G; Gunsilius E; Steurer M
    Blood; 2009 Oct; 114(18):3960-7. PubMed ID: 19713465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
    Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.